Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study

Xenobiotica

Volumn 44, Issue 9, 2014, Pages 849-854

  Ma, Jianshe ^a   Zhang, Qingwei ^b   Wang, Xianqin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Shanghai Institute of Pharmaceutical Industry   (China)

Author keywords

HDAC; LC MS; MGCD0103; Pharmacokinetics; Rat plasma

Indexed keywords

ACETONITRILE; FORMIC ACID; MIDAZOLAM; MOCETINOSTAT; WATER; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY; ELUTION; ION MONITORING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; RAT; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY; ANIMAL; BIOAVAILABILITY; BLOOD; CALIBRATION; QUALITY CONTROL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAMIDES; BIOLOGICAL AVAILABILITY; CALIBRATION; CHROMATOGRAPHY, LIQUID; HISTONE DEACETYLASE INHIBITORS; MALE; MASS SPECTROMETRY; PYRIMIDINES; QUALITY CONTROL; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84905374624     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.897012     Document Type: Article

References (24)

1. Bociek R, Kuruvilla J, Pro B, et al. (2008). Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). J Clin Oncol 26:8507.
2. Campas-Moya C. (2009). Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45:787-95.
3. Crump M, Andreadis C, Assouline S, et al. (2008). Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol 26:Abstract 8528.
4. De Ruijter A, Van Gennip A, Caron H, et al. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-49.
5. European Medicines Agency (EMA). (2011). Guideline on bioanalytical method validation. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2011/08/WC5001096 86.pdf [last accessed 3 Mar 2014].
6. Fournel M, Bonfils C, Hou Y, et al. (2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759-68.
7. Gallinari P, Di Marco S, Jones P, et al. (2007). HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17:195-211.
8. Garcia-Manero G, Assouline S, Cortes J, et al. (2008). Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112:981-9.
9. Glaser KB, Li J, Staver MJ, et al. (2003). Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310:529-36.
10. Grant S, Easley C, Kirkpatrick P. (2007). Vorinostat. Nat Rev Drug Discov 6:21-2.
11. Hassig CA, Schreiber SL. (1997). Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1:300-8.
12. Hu E, Dul E, Sung C-M, et al. (2003). Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720-8.
13. Maiso P, Carvajal-Vergara X, Ocio EM, et al. (2006). The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781-9.
14. Marks PA, Rifkind RA, Richon VM, et al. (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202.
15. McKinsey TA, Zhang CL, Olson EN. (2001). Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 11: 497-504.
16. Minucci S, Pelicci PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51.
17. Qian X, Ara G, Mills E, et al. (2008). Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122:1400-10.
18. Siu LL, Pili R, Duran I, et al. (2008). Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 26:1940-7.
19. Turner BM. (2000). Histone acetylation and an epigenetic code. Bioessays 22:836-45.
20. US Food and Drug Administration. (2001). Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/ Drugs/Guidances/ucm070107.pdf [last accessed 3 Mar 2014].
21. Wang Z, Zang C, Cui K, et al. (2009). Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138:1019-31.
22. Williams JS, Donahue SH, Gao H, Brummel CL. (2012). Universal LC-MS method for minimized carryover in a discovery bioanalytical setting. Bioanalysis 4:1025-37.
23. Younes A, Wedgwood A, McLaughlin P, et al. (2007). Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. Blood 110:2571.
24. Zhou N, Moradei O, Raeppel S, et al. (2008). Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl] benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 51:4072-5.